Review of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitor
Abstract Background Hereditary angioedema with normal C1 inhibitor (HAE-nC1 INH) is a rare, underappreciated condition characterized by recurrent subcutaneous angioedema. The underlying pathophysiology and diagnostic criteria continues to evolve. There is a significant overlap between HAE-nC1 INH an...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | Allergy, Asthma & Clinical Immunology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13223-019-0381-y |
id |
doaj-504054d5a43a490f88a89373a9cf98bf |
---|---|
record_format |
Article |
spelling |
doaj-504054d5a43a490f88a89373a9cf98bf2020-11-25T04:06:41ZengBMCAllergy, Asthma & Clinical Immunology1710-14922019-11-011511510.1186/s13223-019-0381-yReview of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitorLundy McKibbin0Colin Barber1Chrystyna Kalicinsky2Richard Warrington3Section of Allergy and Clinical Immunology, Department of Internal Medicine, Rady Faculty of Medicine, University of ManitobaSection of Allergy and Clinical Immunology, Department of Internal Medicine, Rady Faculty of Medicine, University of ManitobaSection of Allergy and Clinical Immunology, Department of Internal Medicine, Rady Faculty of Medicine, University of ManitobaSection of Allergy and Clinical Immunology, Department of Internal Medicine, Rady Faculty of Medicine, University of ManitobaAbstract Background Hereditary angioedema with normal C1 inhibitor (HAE-nC1 INH) is a rare, underappreciated condition characterized by recurrent subcutaneous angioedema. The underlying pathophysiology and diagnostic criteria continues to evolve. There is a significant overlap between HAE-nC1 INH and idiopathic nonhistaminergic angioedema, ultimately this may be found to be the same condition. Characterization of cohorts suspected to have either of these conditions is warranted to help refine diagnosis, pathophysiology, and treatment response. Methods A retrospective chart review of 418 patients diagnosed with angioedema was conducted. The following inclusion criteria was used: lack of response to antihistamines, steroids, and epinephrine; normal C4, C1 inhibitor (C1 INH) level and function; lack of urticaria or pruritus; occurrence without offending drugs; and positive family history. Enzyme immunoassays for C1 INH function were performed at the Mayo Clinic. Charts meeting these criteria were reviewed for frequency and type of episodes as well as use and response to therapies. Results 6 patients met the above criteria. 3 of these completed genetic testing, none were found to have factor XII abnormalities. None had angiopoietin 1 or plasminogen gene sequencing. 5 of 6 patients were successfully treated with C1 INH or tranexamic acid for acute treatment of attacks (4 with C1 INH and 1 with tranexamic acid). 4 patients have used Icatibant with good response (typically under 40 min for near full recovery); of these, 3 required Icatibant as acute treatment after other therapies (C1 inhibitor and tranexamic acid) were ineffective. There were 9 patients who otherwise met criteria, but due to a lack of family history were classified as having idiopathic non-histaminergic angioedema. Conclusions This retrospective chart review found 6 HAE-nC1 INH patients in Manitoba. 1 responded to tranexamic acid and not C1 INH, 4 typically responded to C1 INH, and 1 responded exclusively to Icatibant. All patients—4 total—who used Icatibant responded; of these 4 patients, 3 required Icatibant after other therapies had failed.http://link.springer.com/article/10.1186/s13223-019-0381-yHereditary angioedema with normal C1 inhibitorType 3 hereditary angioedemaIcatibant |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lundy McKibbin Colin Barber Chrystyna Kalicinsky Richard Warrington |
spellingShingle |
Lundy McKibbin Colin Barber Chrystyna Kalicinsky Richard Warrington Review of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitor Allergy, Asthma & Clinical Immunology Hereditary angioedema with normal C1 inhibitor Type 3 hereditary angioedema Icatibant |
author_facet |
Lundy McKibbin Colin Barber Chrystyna Kalicinsky Richard Warrington |
author_sort |
Lundy McKibbin |
title |
Review of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitor |
title_short |
Review of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitor |
title_full |
Review of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitor |
title_fullStr |
Review of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitor |
title_full_unstemmed |
Review of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitor |
title_sort |
review of the manitoba cohort of patients with hereditary angioedema with normal c1 inhibitor |
publisher |
BMC |
series |
Allergy, Asthma & Clinical Immunology |
issn |
1710-1492 |
publishDate |
2019-11-01 |
description |
Abstract Background Hereditary angioedema with normal C1 inhibitor (HAE-nC1 INH) is a rare, underappreciated condition characterized by recurrent subcutaneous angioedema. The underlying pathophysiology and diagnostic criteria continues to evolve. There is a significant overlap between HAE-nC1 INH and idiopathic nonhistaminergic angioedema, ultimately this may be found to be the same condition. Characterization of cohorts suspected to have either of these conditions is warranted to help refine diagnosis, pathophysiology, and treatment response. Methods A retrospective chart review of 418 patients diagnosed with angioedema was conducted. The following inclusion criteria was used: lack of response to antihistamines, steroids, and epinephrine; normal C4, C1 inhibitor (C1 INH) level and function; lack of urticaria or pruritus; occurrence without offending drugs; and positive family history. Enzyme immunoassays for C1 INH function were performed at the Mayo Clinic. Charts meeting these criteria were reviewed for frequency and type of episodes as well as use and response to therapies. Results 6 patients met the above criteria. 3 of these completed genetic testing, none were found to have factor XII abnormalities. None had angiopoietin 1 or plasminogen gene sequencing. 5 of 6 patients were successfully treated with C1 INH or tranexamic acid for acute treatment of attacks (4 with C1 INH and 1 with tranexamic acid). 4 patients have used Icatibant with good response (typically under 40 min for near full recovery); of these, 3 required Icatibant as acute treatment after other therapies (C1 inhibitor and tranexamic acid) were ineffective. There were 9 patients who otherwise met criteria, but due to a lack of family history were classified as having idiopathic non-histaminergic angioedema. Conclusions This retrospective chart review found 6 HAE-nC1 INH patients in Manitoba. 1 responded to tranexamic acid and not C1 INH, 4 typically responded to C1 INH, and 1 responded exclusively to Icatibant. All patients—4 total—who used Icatibant responded; of these 4 patients, 3 required Icatibant after other therapies had failed. |
topic |
Hereditary angioedema with normal C1 inhibitor Type 3 hereditary angioedema Icatibant |
url |
http://link.springer.com/article/10.1186/s13223-019-0381-y |
work_keys_str_mv |
AT lundymckibbin reviewofthemanitobacohortofpatientswithhereditaryangioedemawithnormalc1inhibitor AT colinbarber reviewofthemanitobacohortofpatientswithhereditaryangioedemawithnormalc1inhibitor AT chrystynakalicinsky reviewofthemanitobacohortofpatientswithhereditaryangioedemawithnormalc1inhibitor AT richardwarrington reviewofthemanitobacohortofpatientswithhereditaryangioedemawithnormalc1inhibitor |
_version_ |
1724431114381033472 |